Recently, the FDA approved the use of pemigatinib for the treatment of adults with previously treated, unresectable locally advanced or metastatic CCA with the FGFR2 fusion or other rearrangements, and it is the first targeted therapy for CCA patients [109]. The gene discussed is FGFR2; the disease is cholangiocarcinoma.